GLP1R and Obesity: In patients with obesity without type 2 diabetes, increased body weight loss after 24 weeks with exenatide plus dapagliflozin was associated with lower basal adiposity and lower basal insulin secretion, as well as with the single-nucleotide polymorphisms rs10010131, a variant associated with the GLP-1 pathway32.